BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies
Although BRIGHTLINE-1 was headlined as a "negative trial," brigimadlin showed clear biological activity, with median PFS of 8.4 months, ORR of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in DDLPS.
Authors
- Adel Shahnam (ORCID: https://orcid.org/0000-0002-0043-8374)
- Mrinal M. Gounder (ORCID: https://orcid.org/0000-0001-8468-0119)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-08-14
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-2134
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00